Dr Raymart Macasaet speaks to ecancer about a real-world analysis that evaluates the impact of tarlatamab in patients with small cell lung cancer (SCLC), focusing on outcomes across different age groups, including older adults.

Results show that overall survival was consistent regardless of age, with no significant differences between patients under 60, 60–70, and over 70 years. The presence of brain metastases also did not significantly affect survival outcomes, highlighting the drug’s broad effectiveness in diverse patient populations.

Immune-related toxicities, including cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, were infrequent and evenly distributed across age groups, with similar rates of supportive interventions such as tocilizumab and vasopressors.